Cargando…

Well-differentiated systemic mastocytosis with KIT K509I mutation and uterus infiltration in an Asian woman with good response to imatinib

Detalles Bibliográficos
Autores principales:	Zhao, Duo-Duo, Zhang, Lu, Li, Wen-Qin, Duan, Ming-Hui, Zhuang, Jun-Ling, Zhou, Dao-Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708691/ https://www.ncbi.nlm.nih.gov/pubmed/31335472 http://dx.doi.org/10.1097/CM9.0000000000000355

Ejemplares similares

Diffuse cutaneous mastocytosis with novel somatic KIT mutation K509I and association with tuberous sclerosis
por: Otani, Iris M., et al.
Publicado: (2018)

Factors contributing to good oocyte competence and utility rates for in vitro fertilization or intracytoplasmic sperm injection in high responders
por: Xue, Wei, et al.
Publicado: (2021)

Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature
por: Alvarez-Twose, Iván, et al.
Publicado: (2016)

Case Report: Evolution of KIT D816V-Positive Systemic Mastocytosis to Myeloid Neoplasm With PDGFRA Rearrangement Responsive to Imatinib
por: Sciumè, Mariarita, et al.
Publicado: (2021)

Validation of the Mayo alliance prognostic system for mastocytosis
por: Mannelli, Francesco, et al.
Publicado: (2019)

World Health Organization class-independent risk categorization in mastocytosis
por: Pardanani, Animesh, et al.
Publicado: (2019)

Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder
por: Chatterjee, Anindya, et al.
Publicado: (2015)

Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis
por: Ke, Hengning, et al.
Publicado: (2016)

IMATINIB INDUCED LICHEN PLANUS
por: Sudha, R, et al.
Publicado: (2011)

Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression
por: Verstovsek, Srdan
Publicado: (2013)

Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors
por: Shomali, William, et al.
Publicado: (2021)

Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: A case report
por: Huang, Lanshan, et al.
Publicado: (2016)

Stone in the Uterus
por: Shah, Chetun
Publicado: (1890)

Prolapse of the Uterus
por: Cook, L.
Publicado: (1914)

Absence of Uterus
por: Gupta, Hari Ch.
Publicado: (1914)

Imatinib-induced Melasma-like Pigmentation
por: Subhadarshani, Sweta, et al.
Publicado: (2019)

Rupture of Uterus with Recovery
por: Brewster, Beatrice A. C.
Publicado: (1911)

Double Uterus and Vagina
por: Jones, Frank A.
Publicado: (1897)

Imatinib-induced Transverse Melanonychia: An Unusual Presentation
por: Das, Anupam, et al.
Publicado: (2015)

Diagnosis and Treatment of Rudimentary Horn Pregnancy: Analysis of Eleven Cases
por: Zhang, Duo-Duo, et al.
Publicado: (2018)

Ovary is necessary to the health of uterus
por: Kim, So-Youn, et al.
Publicado: (2016)

The role of c-kit and imatinib mesylate in uveal melanoma
por: Pereira, Patricia Rusa, et al.
Publicado: (2005)

Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation
por: Zappulla, Jacques P., et al.
Publicado: (2005)

Presumed mast cell choroidal infiltrate in aggressive systemic mastocytosis
por: Tran, Tu M., et al.
Publicado: (2020)

Inversion of the Uterus Combined with Endometrial Carcinosarcoma
por: Zhao, Huan-Huan, et al.
Publicado: (2018)

Belatacept: Good, but not good enough?
por: Parameswaran, Sreejith, et al.
Publicado: (2012)

Lipoleiomyoma of uterus in a postmenopausal woman
por: Manjunatha, Hanumanthappa Krishnappa, et al.
Publicado: (2010)

Loss of Function of TET2 Cooperates with Constitutively Active KIT in Murine and Human Models of Mastocytosis
por: De Vita, Serena, et al.
Publicado: (2014)

Activation of TRKA receptor elicits mastocytosis in mice and is involved in the development of resistance to KIT-targeted therapy
por: Yang, Min, et al.
Publicado: (2017)

Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis
por: Naumann, Nicole, et al.
Publicado: (2021)

Successful Imatinib Treatment for Systemic Mastocytosis Associated With Myelodysplastic/Myeloproliferative Neoplasm: Report of a Case and Literature Review
por: Barozzi, Enrico, et al.
Publicado: (2022)

Imatinib Mesylate-Induced Cutaneous Rash Masquerading as Pityriasis Rosea of Gilbert
por: Verma, Prashant, et al.
Publicado: (2014)

Imatinib is not a potent anti-SARS-CoV-2 drug
por: Zhao, Helong, et al.
Publicado: (2020)

Long-term clinical outcomes of COVID-19 patients treated with imatinib
por: Duijvelaar, Erik, et al.
Publicado: (2022)

The Application of Pressure by the Tampon to the Cavity of the Uterus in Disease of the Endometrium
por: Taliaferro, V. H.
Publicado: (1886)

Rizzoli’s Osteoklast; Hegar’s Operation for Fibroid of the Uterus; Akystopeurastic
por: Senn, N.
Publicado: (1878)

SAT-509 Sudden Onset of Malabsorption
por: Mroueh, Gabriela, et al.
Publicado: (2020)

Prostate biopsy and fiducial placement in the same sitting- a good option during COVID pandemic as well as in patients on anticoagulants/antiplatelets
por: Sen, Anitha, et al.
Publicado: (2021)

Cutaneous mastocytosis with a mutation in the juxtamembrane domain of c-kit in a young laboratory beagle dog
por: Kato, Yuki, et al.
Publicado: (2015)

New Approach to Paediatric Mastocytosis: Implications of KIT D816V Mutation Detection in Peripheral Blood
por: CZARNY, Justyna, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_oo97n1ct8j70mqk9tr0h6ka0p8